16. Ibrance

Ibrance flopped a major breast cancer trial back in May. (Pfizer)

Company: Pfizer
2019 sales: $4.96 billion
Projected 2026 sales: $11.04 billion
Projected CAGR: +12%
Used for: HR-postiive, HER2-negative breast cancer

Pfizer's oncology med Ibrance has been a sales superstar since its launch in 2015, and for years execs forecast even brighter days ahead with a move earlier into therapy. A continued sales climb would be great for Pfizer, which is looking for for growth drivers after its planned generics unit spinoff—but they may not come in that arena.

Ibrance hit $4.96 billion in sales in 2019 on the strength of its market share in HR-positive, HER2-negative breast cancer. And there's even more room for growth: Evaluate Pharma predicts the drug could climb all the way to $11.04 billion in sales by 2026, putting it among pharma's sales elites. 

But Ibrance missed a huge opportunity at a multibillion-dollar market when it flopped a major early breast cancer trial in May.

RELATED: Pfizer's Ibrance misses shot at big new market with early breast cancer failure

16. Ibrance